Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Dassault Systèmes SE
  6. News
  7. Summary
    DSY   FR0000130650

DASSAULT SYSTÈMES SE

(DSY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes : Medidata Launches myMedidata Registries to Transform Awareness, Access, and Retention of Patients in Clinical Trials

06/10/2021 | 04:08am EDT

New York, New York - - Medidata, a Dassault Systemes company, today launched myMedidata Registries, a new technology that expands and strengthens the myMedidata patient portal to engage patients before and after (i.e., long term follow up/safety surveillance) a clinical trial. This empowers patients to learn more about clinical trial opportunities and provides an experience that allows for active participation throughout their clinical trial journey. With increasing interest and adoption of decentralized clinical trials, myMedidata Registries gives patients continuous support in and out of a trial with access to one portal for all of their research needs - providing an everlasting engagement on one portal for life.

Issues surrounding patient awareness of and access to clinical trials have been roadblocks to participation for many years. According to the Center for Information and Study on Clinical Research Participation (CISCRP), only 25 percent of individuals reported being "very confident" in their ability to find a clinical research study.1 Furthermore, 98 percent of individuals surveyed were willing to participate in another study, yet many reported they never heard back from anyone after the study was completed, be it clinical trial results, patient data return, a thank you note, or an invitation to a new study.2 These individuals are never engaged and the traditional recruitment cycle starts anew with each upcoming trial.

"The time for myMedidata Registries is now," said Anne Marie Mercurio, a distinguished patient advocate and caregiver, and a member of Medidata's Patient Insights team. "The patient community needs a quick, easy, secure way to get engaged with clinical research. My message is: Don't miss out - the more who join, the faster we can get the scientific evidence to better understand and treat diseases."

Built directly on the Medidata Clinical Cloud, the only unified technology platform dedicated to clinical research, myMedidata Registries provides education, pre-screening, patient data collection, and opportunities for video visits before a patient travels to a site or is enrolled into a study. Clinical trial sponsors and CROs using myMedidata Registries have a direct, secure connection with trial participants via notifications and alerts, allowing them to optimize trial participation, and increase product and trial awareness.

"myMedidata Registries is designed to transform patients' clinical trial experiences from being a transactional and impersonal process to a seamless and engaging one that deepens relationships between participants, sponsors, and trial sites," said Kelly McKee, Vice President, Patient Registries and Recruitment at Medidata. "This redefines Medidata's end-to-end technology solutions and represents a major advance for the life science industry, providing patients with a new option to pursue care." See how the registry works by clicking here.

myMedidata Registries - first introduced in the US and with other countries to follow - provides sponsors with one, unified ecosystem for patient identification, study execution and end-of-study patient communications, including patient data return. Once a new therapeutic, vaccine or medical device is on the market, myMedidata Registries allows sponsors and CROs to continue to engage with participants when long term follow up (LTFU) and safety monitoring is required. Regulators require LTFU for thousands of studies, with human gene therapies needing 15 to 30 years or more. Additionally, myMedidata Registries can be used to bridge patients moving from Phase 2/3 to Phase 4 clinical trials.

Medidata Patient Insights and Patient Centricity by Design

myMedidata Registries was designed for patients by patients, in partnership with Medidata's Patient Insights team. Medidata's team of dedicated patient advocates uses the Patient Centricity by Design (PCbD) process that infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research interactions. The PCbD initiative was named the first-place winner at the 2021 SCOPE Participant Engagement Awards.

The myMedidata Patient Portal

myMedidata is a web-based, single-destination patient portal,encompassing all of the capabilities of Medidata's patient-facing solutions for electronic consent and clinical outcomes assessment (eCOA) along with live video investigator/patient visits using myMedidata LIVE all through one web-based intuitive interface. With myMedidata, patients can use any online device to virtually learn, enroll and participate in clinical trial activities. With more than 20 years of innovation, Medidata offers a streamlined and trusted approach to decentralized clinical trials.

Medidata is a wholly owned subsidiary of Dassault Systemes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

https://www.ciscrp.org/education-center/charts-statistics/

https://www.ciscrp.org/wp-content/uploads/2019/12/Participation-Experiences-04DEC-1.pdf

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about DASSAULT SYSTÈMES SE
07/28DASSAULT SYSTEMES COMMITS FOR SUSTAI : Science-Based Targets Approved and Net Ze..
AQ
07/28DASSAULT SYSTEMES : Boticário Group Digitally Transforms the Manufacturing of 30..
AQ
07/27DASSAULT SYSTÈMES : Availability of the 2021 Half-Year Financial Report
GL
07/27DASSAULT SYSTEMES : Systèmes Touts Virtual Technology As First-Half Software Rev..
MT
07/27Dassault Systèmes Se Reports Earnings Results for the Second Quarter Ended Ju..
CI
07/27Dassault Systemes lifts 2021 outlook on surging software sales
RE
07/27DASSAULT SYSTEMES : Systèmes Targets Net-Zero Emissions By 2040
MT
07/27DASSAULT SYSTEMES : Systèmes' H1 Earnings Rise 28%, Full-Year Guidance Raised
MT
07/27DASSAULT SYSTEMES : Systèmes Reports Strong Second Quarter Results, Raises Full ..
GL
07/27DASSAULT SYSTEMES : Boticário Group Digitally Transforms the Manufacturing of 30..
GL
More news
Financials
Sales 2021 4 805 M 5 700 M 5 700 M
Net income 2021 756 M 897 M 897 M
Net Debt 2021 1 093 M 1 297 M 1 297 M
P/E ratio 2021 79,5x
Yield 2021 0,35%
Capitalization 60 399 M 71 801 M 71 646 M
EV / Sales 2021 12,8x
EV / Sales 2022 11,4x
Nbr of Employees 20 000
Free-Float 50,0%
Chart DASSAULT SYSTÈMES SE
Duration : Period :
Dassault Systèmes SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DASSAULT SYSTÈMES SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 45,97 €
Average target price 44,28 €
Spread / Average Target -3,67%
EPS Revisions
Managers and Directors
Bernard Charlès Vice Chairman & Chief Executive Officer
Dominique Florack President
Pascal Daloz Chief Operating & Financial Officer
Charles Edelstenne Chairman
Laurence Barthès Executive VP, Chief People & Information Officer
Sector and Competitors
1st jan.Capi. (M$)
DASSAULT SYSTÈMES SE38.32%71 801
MICROSOFT CORPORATION28.81%2 154 194
SEA LIMITED43.19%149 469
ZOOM VIDEO COMMUNICATIONS, INC.13.35%114 633
ATLASSIAN CORPORATION PLC14.08%67 013
ROBLOX CORPORATION0.00%43 792